Late-stage trials prove efficacy of obesity drug Contrave

07/20/2009 | Google

Three Phase III trials showed that patients who took Orexigen Therapeutics' obesity drug Contrave lost more weight than those on placebo. The product, which is a combination of antidepressant bupropion and addiction treatment naltrexone, also improved levels of "good" HDL cholesterol in patients and reduced risk factors such as waist circumference.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA